Sheldon H. Preskorn, M.D., is President and Chief Executive Officer for the Clinical Research Institute and Professor in the Department of Psychiatry at the University of Kansas School of Medicine-Wichita (KUSM-W).

A fellow of the American Psychiatric Association and the American Psychopathological Association, Dr. Preskorn has served on advisory committees of the Food and Drug Administration, Veterans Administration, National Institutes of Health and National Science Foundation, and was a consultant to the Menninger Foundation on clinical psychopharmacology.

He received his MD degree at the University of Kansas, Kansas City, Kansas. He completed a two-year residency in anatomical pathology (with emphasis on neuropathology) and a one-year rotating internship in internal medicine and psychiatry at the University of Kansas Medical Center, Kansas City, Kansas and his residency in psychiatry at Washington University School of Medicine, St. Louis, Missouri. He has undergraduate degree in psychobiology (psychology, biology and chemistry) and postgraduate medical training in anatomical pathology (neuropathology), psychiatry, and basic and clinical pharmacology.

An international lecturer and the author of over 400 scientific, professional articles and books. Dr. Preskorn has received continuous grant funding since 1978 for an estimated life-time total of 50 million dollars. This funding has allowed him to pursue research in psychopharmacology and neuroscience of psychiatric illnesses.

His basic pharmacological and neuroscience research has included studies in learning theory, neurochemistry, neurophysiology, histochemistry, electron microscopy, cerebral blood flow and metabolism, positron emission tomography and radioligand binding.

His clinical research has included pharmacokinetics, drug-drug interactions, and drug development through all clinical phases from "first time in man" studies through phase III trials. He has been the principal investigator on over 250 clinical trials including drug development studies of all antidepressants marketed in the United States in the last 25 years. He also has extensive experience with the drug registration process having been involved in the registration process for 8 of the 12 antidepressants marketed in the United States over the last 25 years and the only implantable device approved for the treatment of a psychiatric illness.

In addition to this research work, his clinical and administrative experience includes six years as supervising physician for an acute psychosis ward, six years as chief of psychiatry for a university affiliated Veterans Administration Medical Center, five years as director of the KUSM-W Outpatient Psychiatric Clinic and eight years as Chair of the KUSM-W Department of Psychiatry.